从影像异质性到临床决策:基于骨髓动力学的影像生物标志物用于晚期NSCLC部分缓解患者
本研究回顾性分析51例晚期非小细胞肺癌(NSCLC)患者,其中32例一线治疗后达部分缓解,利用治疗前动态18F-FDG PET/CT的骨髓动力学异质性构建影像生物标志物。通过bootstrap-LASSO-Cox筛选出骨髓游离FDG时间-活性曲线10-30分钟斜率(BM_Cf_Slope10-30)为最显著独立预测因子,该特征与进展风险降低强相关,并有效分层高风险与低风险组。
要点
- 动态18F-FDG PET/CT骨髓动力学特征可预测晚期NSCLC部分缓解患者的进展风险。
- BM_Cf_Slope10-30是多变量Cox模型中最显著的独立预测因子(HR=0.10)。
- 简化风险分层模型在12、18、24个月的平均时间依赖AUC分别为0.792、0.774、0.731。
核心结论
- 治疗前动态18F-FDG PET/CT评估骨髓动力学可作为晚期NSCLC部分缓解患者的潜在预后生物标志物。
研究设计与样本
- 回顾性分析51例晚期NSCLC患者,聚焦其中32例一线治疗后达部分缓解者。
- 从肿瘤和骨髓提取时间-活性曲线(TAC)并进行代谢分解,整合临床特征、常规PET参数和28个TAC衍生特征。
- 采用bootstrap-LASSO-Cox程序(1000次重采样)进行稳健特征筛选,构建多变量Cox模型和简化风险分层模型。
主要发现
- bootstrap-LASSO-Cox分析识别骨髓游离FDG TAC在注射后10至30分钟的斜率(BM_Cf_Slope10-30)为最显著独立预测因子。
- 多变量Cox模型中该特征与进展风险降低强相关(HR=0.10,95%CI:0.03-0.35,P<0.001),区分能力良好(C-index=0.77,95%CI:0.68-0.86)。
- 以最佳截断值-0.01119可将患者显著分层为高风险和低风险组,两组无进展生存期差异显著(Log-rank P<0.001)。
- 简化模型在12、18、24个月的平均时间依赖AUC分别为0.792、0.774、0.731,并提供临床净获益。
- 常规代谢参数和临床特征均未显示显著预测价值。
关键数值与推荐
- BM_Cf_Slope10-30的最佳截断值为-0.01119,用于分层高风险与低风险组。
- 多变量Cox模型中BM_Cf_Slope10-30的HR=0.10(95%CI:0.03-0.35,P<0.001),C-index=0.77(95%CI:0.68-0.86)。
- 简化模型12、18、24个月平均时间依赖AUC分别为0.792、0.774、0.731。
临床怎么用
- 对一线治疗后达部分缓解的晚期NSCLC患者,可考虑治疗前动态18F-FDG PET/CT评估骨髓动力学以识别早期进展高风险者。
- BM_Cf_Slope10-30反映早期间质清除,可辅助个体化监测策略和及时治疗干预决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Risk of disease progression varies substantially among advanced non-small cell lung cancer (NSCLC) patients who achieve a partial response to initial therapy, and this subgroup currently lacks practical prognostic tools. This study aimed to develop a novel imaging biomarker by assessing bone marrow kinetic heterogeneity via pretreatment dynamic 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT). We retrospectively analyzed 51 patients with advanced NSCLC, focusing on the 32 who attained a partial response following first-line treatment. Time-activity curves (TACs) from the tumor and bone marrow were metabolically decomposed. Through integrated analysis of clinical characteristics, conventional PET parameters, and 28 TAC-derived features, coupled with a rigorous bootstrap-LASSO-Cox procedure (1000 resamples) for robust feature selection, we developed a multivariate Cox model and a simplified risk-stratification model. RESULTS: The bootstrap-LASSO-Cox analysis identified the slope of the bone marrow free FDG TAC between 10 and 30 min post-injection (BM_Cf_Slope10-30) as the most significant independent predictor. In the multivariate Cox model, this feature was strongly associated with a reduced risk of progression (Hazard Ratio = 0.10, 95% CI: 0.03-0.35, P < 0.001) and demonstrated good discriminative ability (C-index = 0.77, 95% CI: 0.68-0.86). Using an optimal cutoff value of -0.01119, this single parameter significantly stratified patients into high- and low-risk groups with distinct progression-free survival (Log-rank P < 0.001). The simplified model showed robust predictive performance, with average time-dependent AUCs of 0.792, 0.774, and 0.731 at 12, 18, and 24 months, respectively, and provided clinical net benefit. Neither conventional metabolic parameters nor clinical characteristics showed significant predictive value. CONCLUSION: For advanced NSCLC patients achieving an initial partial response, pretreatment assessment of bone marrow kinetics via dynamic 18F-FDG PET/CT emerges as a potential prognostic biomarker. The TAC slope feature, which reflects early interstitial clearance, can identify patients at high risk of early progression, offering potential for personalizing surveillance strategies and guiding timely therapeutic interventions.
引用
- Wang Y, Yao Z, Wan J, et al. From imaging heterogeneity to clinical decision: a novel imaging biomarker based on bone marrow kinetics for advanced NSCLC patients in partial response. EJNMMI Res. 2026. PMID: 42168673. doi:10.1186/s13550-026-01440-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。